Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-008107
Date:2021-02-03
Issuer: TRAVERE THERAPEUTICS, INC. (TVTX)
Original Submission Date:

Reporting Person:

DUBE ERIC M
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO, CA 92130

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-02-03 A 17,500 a $0.00 166,439 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 (1) on january 31, 2020, the reporting person was granted a performance restricted stock unit (prsu) grant covering 35,000 shares of the issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. on february 3, 2021, a portion of the prsus vested upon the issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the duplex study.

Elevate your investments